Mereo Biopharma Group Plc ADR [MREO] stock prices are down -21.14% to $0.38 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MREO shares have gain 32.80% over the last week, with a monthly amount drifted -81.42%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Mereo Biopharma Group Plc ADR [NASDAQ: MREO] stock has seen the most recent analyst activity on December 30, 2025, when Jefferies downgraded its rating to a Hold but kept the price target unchanged to $0.50 for it. Previously, JP Morgan started tracking the stock with Overweight rating on March 27, 2025, and set its price target to $7. On December 06, 2024, Jefferies initiated with a Buy rating and assigned a price target of $7 on the stock. Robert W. Baird started tracking the stock assigning an Outperform rating and suggested a price target of $8 on June 13, 2024. Cantor Fitzgerald started tracking with an Overweight rating for this stock on August 12, 2022, and assigned it a price target of $4. In a note dated May 05, 2021, BTIG Research initiated a Buy rating and provided a target price of $10 on this stock.
The stock price of Mereo Biopharma Group Plc ADR [MREO] has been fluctuating between $0.20 and $3.84 over the past year. Currently, Wall Street analysts expect the stock to reach $1.88 within the next 12 months. Mereo Biopharma Group Plc ADR [NASDAQ: MREO] shares were valued at $0.38 at the most recent close of the market. An investor can expect a potential return of 394.74% based on the average MREO price forecast.
Analyzing the MREO fundamentals
Gross Profit Margin for this corporation currently stands at 0.19% with Operating Profit Margin at -93.7%, Pretax Profit Margin comes in at -84.16%, and Net Profit Margin reading is -83.02%. To continue investigating profitability, this company’s Return on Assets is posted at -0.77, Equity is -0.75 and Total Capital is -0.98. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.3296 points at the first support level, and at 0.2803 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.4678, and for the 2nd resistance point, it is at 0.5567.
Ratios To Look Out For
It’s worth pointing out that Mereo Biopharma Group Plc ADR [NASDAQ:MREO]’s Current Ratio is 8.71. As well, the Quick Ratio is 8.71, while the Cash Ratio is 8.09. Considering the valuation of this stock, the price to sales ratio is 118.23, the price to book ratio is 1.29.
